Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent

Nucleic Acids Research

Volumn 35, Issue 11, 2007, Pages 3581-3589

  Evison, Ben J ^a   Mansour, Oula C ^a   Menta, Ernesto ^b   Phillips, Don R ^a   Cutts, Suzanne M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b Cell Therapeutics Europe   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DNA; DOUBLE STRANDED DNA; FORMALDEHYDE; MITOXANTRONE; PIXANTRONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DNA ADDUCT; DNA CROSS LINKING; DNA DENATURATION; DRUG DNA BINDING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THERMOSTABILITY; CHEMISTRY; KINETICS; PH; TEMPERATURE;

ANTINEOPLASTIC AGENTS; DNA ADDUCTS; FORMALDEHYDE; HYDROGEN-ION CONCENTRATION; ISOQUINOLINES; KINETICS; TEMPERATURE;

EID: 34547134519     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkm285     Document Type: Article

References (43)

1. Creighton,T.E. (1999) Encyclopedia of Molecular Biology. Wiley, New York, Chichester.
2. Hellman,S., DeVita,V.T. and Rosenberg,S.A. (2001) Cancer: Principles & Practice of Oncology, 6th edn. Lippincott-Raven, Philadelphia, London.
3. Murdock,K.C., Child,R.G., Fabio,P.F., Angier,R.B., Wallace,R.E., Durr,F.E. and Citarella,R.V. (1979) Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J. Med. Chem., 22, 1024-1030.
4. Wallace,R.E., Murdock,K.C., Angier,R.B. and Durr,F.E. (1979) Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res., 39, 1570-1574.
5. Zee-Cheng,R.K. and Cheng,C.C. (1978) Antineoplastic agents. Structure-activity relationship study of bis(substituted amino-alkylamino)anthraquinones. J. Med. Chem., 21, 291-294.
6. Durr,F.E. (1988) In Lown,JW (ed.), Anthracycline and Anthracenedione-based Anticancer Agents. Elsevier, Amsterdam, The Netherlands, pp. 163-200.
7. Pratt,W.B., Ruddon,R.W., Ensminger,W.D. and Maybaum,J. (1994) The Anticancer Drugs, 2nd edn. Oxford University Press, New York, USA.
8. Smith,P.J., Morgan,S.A., Fox,M.E. and Watson,J.V. (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem. Pharmacol., 40, 2069-2078.
9. Davies,S.M., Robson,C.N., Davies,S.L. and Hickson,I.D. (1988) Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J. Biol. Chem. 263, 17724-17729.
10. Burden,D.A. and Osheroff,N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139-154.
11. Cornbleet,M.A., Stuart-Harris,R.C., Smith,I.E., Coleman,R.E., Rubens,R.D., McDonald,M., Mouridsen,H.T., Rainer,H., van Oosterom,A.T. et al. (1984) Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. Eur. J. Cancer Clin. Oncol., 20, 1141-1146.
12. Faulds,D., Balfour,J.A., Chrisp,P. and Langtry,H.D. (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 41 400-449.
13. Pratt,W.B. and Pratt,W.B. (1994) The Anticancer Drugs, 2nd edn. Oxford University Press, New York, USA.
14. Corbett,T.H., Griswold,D.P.Jr, Roberts,B.J. and Schabel,M.Jr. (1981) Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother. Pharmacol., 6, 161-168.
15. Krapcho,A.P., Petry,M.E., Getahun,Z, Landi,J.J.Jr., Stallman,J., Polsenberg,J.F., Gallagher,C.E., Maresch,M.J., Hacker,M.P. et al. (1994) 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinotine-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9, 10-diones: synthesis and antitumor evaluations. J. Med. Chem., 37, 828-837.
16. Krapcho,A.P., Landi,J.J.Jr., Hacker,M.P. and Mccormack,J.J. (1985) Synthesis and antineoplastic evaluations of 5,8-bisi(amino-alkyl) aminol-1-azaanthracene-9,10-diones. J. Med. Chem., 28, 1124-1126.
17. Krapcho,A.P., Maresch,M.J, Helgason,A.L., Rosner,K.E., Hacker,M.P., Spinelli,S., Menta,E. and Oliva,A. (1993) The synthesis of 6,9-bis-[(aminoalkyl)amino] substituted benzo[g]quinoxatine-, benzo[g]quinazohne- and benzo[g]phthalazine-5,10-diones via regiospecific displacements. J. Heterocyclic. Chem., 30, 1597-1606.
18. Krapcho,A.P., Maresch,M.J., Hacker,M.P., Menta,E., Oliva,A., Giuliani,F.C. and Spinelli,S. (1995) Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Acta Biochim. Pol., 42, 427-432.
19. Beggiolin,G., Crippa,L., Menta,E., Manzotti,C., Cavalletti,E., Pezzoni,G., Torriani,D., Randisi,E., Cavagnoli,R. et al. (2001) Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori, 87, 407-416.
20. Borchmann,P. and Reiser,M. (2003) Pixantrone (Novuspharma). IDrugs 6, 486-490.
21. De Isabella,P., Palumbo,M., Sissi,C., Capranico,G., Carenini,N., Menta,E., Oliva,A., Spinelli,S., Krapcho,A.P. et al. (1995) Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol., 48 30-38.
22. Hazlehurst,L.A., Krapcho,A.P. and Hacker,M.P. (1995) Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem. Pharmacol., 50, 1087-1094.
23. Hazlehurst,L.A., Krapcho,A.P. and Hacker,M.P. (1995) Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett., 919, 115-124.
24. Zwelling,L.A., Mayes,J., Altschuler,E., Satitpunwaycha,P., Tritton,T.R. and Hacker,M.P. (1993) Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem. Pharmacol., 46 265-271.
25. Reszka,K., Hartley,J.A., Kolodziejczyk,P. and Lown,J.W. (1989) Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug. Biochem. Pharmacol., 38, 4253-4260.
26. Panousis,C., Kettle,A.J. and Phillips,D.R. (1994) Oxidative metabolism of mitoxantrone by the human neutrophil enzyme myeloperoxidase. Biochem. Pharmacol., 48, 2223-2230.
27. Panousis,C., Kettle,A.J. and Phillips,D.R. (1995) Myeloperoxidase oxidizes mitoxantrone to metabolites which bind covalently to DNA and RNA. Anticancer Drug Des., 10, 593-605.
28. Taatjes,D.J., Gaudiano,G., Resing,K. and Koch,T.H. (1996) Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem., 39, 4135-4138.
29. Parker,B.S., Cullinane,C. and Phillips,D.R. (1999) Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res. 27, 2918-2923.
30. Parker,B.S., Cutts,S.M., Cullinane,C. and Phillips,D.R. (2000) Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. Nucleic Acids Res., 28, 982-990.
31. Parker,B.S., Cutts,S.M. and Phillips,D.R. (2001) Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides. J. Biol. Chem., 276, 15953-15960.
32. Parker,B.S., Rephaeli,A., Nudelman,A., Phillips,D.R. and Cutts,S.M. (2004) Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation. Oncol. Res., 14, 279-290.
33. Luce,R.A., Sigurdsson,S.T. and Hopkins,P.B. (1999) Quantification of formaldehyde-mediated covalent adducts of adriamycin with DNA. Biochemistry, 38, 8682-8690.
34. Vos,J.M. (1988) In Friedberg,EC and Hanawalt,PC (eds), DNA Repair: A Laboratory Manual of Research Procedures. Marcel Dekker, NY, Vol. 3, pp. 367-398.
35. Cutts,S.M., Rephaeli,A., Nudelman,A., Hmelnitsky,I. and Phillips,D.R. (2001) Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res., 61, 8194-8202.
36. Iborra,F.J., Renau-Piqueras,J., Portoles,M., Boleda,M.D., Guerri,C. and Pares,X. (1992) Immunocytochemical and biochemical demonstration of formaldhyde dehydrogenase (class III alcohol dehydrogenase) in the nucleus. J. Histochem. Cytochemn., 40, 1965-1878.
37. Thorndike,J. and Beck,W.S. (1977) Production of formaldehyde from N5-methyltetrahydrofolate by normal and leukemic leukocytes. Cancer Res., 37, 1125-1132.
38. Borchmann,P., Morschhauser,F., Parry.A., Schnell,R., Harousseau,J.L., Gisselbrecht,C., Rudolph,C., Wilhelm,M., Gunther,H. et al. (2003) Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica, 88, 888-894.
39. Borchmann,P., Schnell,R., Knippertz,R., Staak,J.O., Camboni,G.M., Bernareggi,A., Hubel,K., Staib,P., Schulz,A. et al. (2001) Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol., 12, 661-667.
40. Kato,S., Burke,P.J., Koch,T.H. and Bierbaum,V.M. (2001) Formaldehyde in human cancer cells: Detection by preconcentration-chemical ionization mass spectrometry. Anal. Chem., 73, 2992-2997.
41. Hah,S.S., Stivers,K.M., de Vere White,R.W. and Henderson,P.T. (2006) Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem. Res. Toxicol., 19, 622-626.
42. Rephaeli,A., Rabizadeh,E., Aviram,A., Shaklai,M., Ruse,M. and Nudelman,A. (1991) Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer, 49, 66-72.
43. Swift,L.P., Rephaeli,A., Nudelman,A., Phillips,D.R. and Cutts,S.M. (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res., 66, 4863-4871.